Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis

Yuqi Guo, Tao Yu, Jian Yang, Tianqing Zhang, Yang Zhou, Fan He, Zoya Kurago, David Myssiorek, Yingjie Wu, Peng Lee, Xin Li

Research output: Contribution to journalArticle

Abstract

The inhibitory effects of metformin have been observed in many types of cancer. However, its effect on human salivary gland carcinoma is unknown. The effect of metformin alone or in combination with pp242 (an mTOR inhibitor) on salivary adenocarcinoma cells growth were determined in vitro and in vivo. We found that metformin suppressed HSY cell growth in vitro in a time and dose dependent manner associated with a reduced expression of MYC onco-protein, and the same inhibitory effect of metformin was also confirmed in HSG cells. In association with the reduction of MYC onco-protein, metformin significantly restored p53 tumor suppressor gene expression. The distinctive effects of metformin and PP242 on MYC reduction and P53 restoration suggested that metformin inhibited cell growth through a different pathway from PP242 in salivary carcinoma cells. Furthermore, the anti-tumor efficacy of metformin was confirmed in vivo as indicated by the increases of tumor necrosis and reduced proliferation in xenograft tumors from metformin treated group. For the first time, the inhibitory effect of metformin on human salivary gland tumor cells was documented. Moreover, metformin inhibitory effects were enhanced by mTOR inhibitor suggesting that metformin and mTOR inhibitor utilize distinctive signaling pathways to suppress salivary tumor growth.

Original languageEnglish (US)
Pages (from-to)3600-3611
Number of pages12
JournalAmerican Journal of Cancer Research
Volume5
Issue number12
StatePublished - 2015

Fingerprint

Metformin
Cell Cycle Checkpoints
Adenocarcinoma
Apoptosis
Growth
Neoplasms
Carcinoma
Glandular and Epithelial Neoplasms
Salivary Glands
Tumor Suppressor Genes
Heterografts
Proteins
Necrosis

Keywords

  • HSG cells
  • HSY cells
  • Metformin
  • Salivary adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis. / Guo, Yuqi; Yu, Tao; Yang, Jian; Zhang, Tianqing; Zhou, Yang; He, Fan; Kurago, Zoya; Myssiorek, David; Wu, Yingjie; Lee, Peng; Li, Xin.

In: American Journal of Cancer Research, Vol. 5, No. 12, 2015, p. 3600-3611.

Research output: Contribution to journalArticle

Guo, Y, Yu, T, Yang, J, Zhang, T, Zhou, Y, He, F, Kurago, Z, Myssiorek, D, Wu, Y, Lee, P & Li, X 2015, 'Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis', American Journal of Cancer Research, vol. 5, no. 12, pp. 3600-3611.
Guo, Yuqi ; Yu, Tao ; Yang, Jian ; Zhang, Tianqing ; Zhou, Yang ; He, Fan ; Kurago, Zoya ; Myssiorek, David ; Wu, Yingjie ; Lee, Peng ; Li, Xin. / Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis. In: American Journal of Cancer Research. 2015 ; Vol. 5, No. 12. pp. 3600-3611.
@article{8f5f67f2c9b1488ba99ca7cf374ccb55,
title = "Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis",
abstract = "The inhibitory effects of metformin have been observed in many types of cancer. However, its effect on human salivary gland carcinoma is unknown. The effect of metformin alone or in combination with pp242 (an mTOR inhibitor) on salivary adenocarcinoma cells growth were determined in vitro and in vivo. We found that metformin suppressed HSY cell growth in vitro in a time and dose dependent manner associated with a reduced expression of MYC onco-protein, and the same inhibitory effect of metformin was also confirmed in HSG cells. In association with the reduction of MYC onco-protein, metformin significantly restored p53 tumor suppressor gene expression. The distinctive effects of metformin and PP242 on MYC reduction and P53 restoration suggested that metformin inhibited cell growth through a different pathway from PP242 in salivary carcinoma cells. Furthermore, the anti-tumor efficacy of metformin was confirmed in vivo as indicated by the increases of tumor necrosis and reduced proliferation in xenograft tumors from metformin treated group. For the first time, the inhibitory effect of metformin on human salivary gland tumor cells was documented. Moreover, metformin inhibitory effects were enhanced by mTOR inhibitor suggesting that metformin and mTOR inhibitor utilize distinctive signaling pathways to suppress salivary tumor growth.",
keywords = "HSG cells, HSY cells, Metformin, Salivary adenocarcinoma",
author = "Yuqi Guo and Tao Yu and Jian Yang and Tianqing Zhang and Yang Zhou and Fan He and Zoya Kurago and David Myssiorek and Yingjie Wu and Peng Lee and Xin Li",
year = "2015",
language = "English (US)",
volume = "5",
pages = "3600--3611",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "12",

}

TY - JOUR

T1 - Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis

AU - Guo, Yuqi

AU - Yu, Tao

AU - Yang, Jian

AU - Zhang, Tianqing

AU - Zhou, Yang

AU - He, Fan

AU - Kurago, Zoya

AU - Myssiorek, David

AU - Wu, Yingjie

AU - Lee, Peng

AU - Li, Xin

PY - 2015

Y1 - 2015

N2 - The inhibitory effects of metformin have been observed in many types of cancer. However, its effect on human salivary gland carcinoma is unknown. The effect of metformin alone or in combination with pp242 (an mTOR inhibitor) on salivary adenocarcinoma cells growth were determined in vitro and in vivo. We found that metformin suppressed HSY cell growth in vitro in a time and dose dependent manner associated with a reduced expression of MYC onco-protein, and the same inhibitory effect of metformin was also confirmed in HSG cells. In association with the reduction of MYC onco-protein, metformin significantly restored p53 tumor suppressor gene expression. The distinctive effects of metformin and PP242 on MYC reduction and P53 restoration suggested that metformin inhibited cell growth through a different pathway from PP242 in salivary carcinoma cells. Furthermore, the anti-tumor efficacy of metformin was confirmed in vivo as indicated by the increases of tumor necrosis and reduced proliferation in xenograft tumors from metformin treated group. For the first time, the inhibitory effect of metformin on human salivary gland tumor cells was documented. Moreover, metformin inhibitory effects were enhanced by mTOR inhibitor suggesting that metformin and mTOR inhibitor utilize distinctive signaling pathways to suppress salivary tumor growth.

AB - The inhibitory effects of metformin have been observed in many types of cancer. However, its effect on human salivary gland carcinoma is unknown. The effect of metformin alone or in combination with pp242 (an mTOR inhibitor) on salivary adenocarcinoma cells growth were determined in vitro and in vivo. We found that metformin suppressed HSY cell growth in vitro in a time and dose dependent manner associated with a reduced expression of MYC onco-protein, and the same inhibitory effect of metformin was also confirmed in HSG cells. In association with the reduction of MYC onco-protein, metformin significantly restored p53 tumor suppressor gene expression. The distinctive effects of metformin and PP242 on MYC reduction and P53 restoration suggested that metformin inhibited cell growth through a different pathway from PP242 in salivary carcinoma cells. Furthermore, the anti-tumor efficacy of metformin was confirmed in vivo as indicated by the increases of tumor necrosis and reduced proliferation in xenograft tumors from metformin treated group. For the first time, the inhibitory effect of metformin on human salivary gland tumor cells was documented. Moreover, metformin inhibitory effects were enhanced by mTOR inhibitor suggesting that metformin and mTOR inhibitor utilize distinctive signaling pathways to suppress salivary tumor growth.

KW - HSG cells

KW - HSY cells

KW - Metformin

KW - Salivary adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84976243066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976243066&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84976243066

VL - 5

SP - 3600

EP - 3611

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 12

ER -